Nora M

Technology Strategy | Organizational Development | Innovation & Partnerships

📍 United States🔄 Updated September 2026💼 1 investments📅 7 years investing🗓 Last invested Jan 2019
VC🌍 United States
1
Total investments
0
Early stage
0
Mid stage
1
Late stage
7y
Years active

Portfolio

1 investments · sorted by recency
All investments
Early stage
Mid stage
Late stage
Angel Investor | Strategic Advisor
2019
BenevolentAI was founded in 2013 to improve quality of life and protect our way of life through technology. That belief has guided everything weve built. Today, theres more scientific knowledge being created than any human can process. We build AI systems that help humanity make sense of it - technology that can read, reason across, and explain the worlds biomedical knowledge. Our approach proved its value when our AI identified baricitinib as a potential Covid-19 treatment within 48 hours, a drug that went on to save lives globally. That wasnt about replacing scientists but extending what they could achieve. Now were making that capability accessible to the broader life sciences ecosystem through Qor, our strategic decision intelligence platform for biotech leaders. Technology in service of life. BenevolentAI is headquartered in London, UK.
Experience · 2 entries
All (2)
Investments (1)
2021
External Advisor | Scientific & Partnership Strategy
2021
Atomwise is a preclinical pharma company revolutionizing how drugs are discovered with AI. Atomwise has strengthened its drug discovery and development expertise by expanding its Board of Directors and creating a Scientific Advisory Board (SAB). These appointments signal a critical milestone for Atomwise as the company focuses on its own internal pipeline. We invented the use of deep learning for structure-based drug discovery, today developing a pipeline of small-molecule drug candidates advancing into preclinical studies. Our AtomNet® technology has been used to unlock more undruggable targets than any other AI drug discovery platform. We are tackling over 600 unique disease targets with more than 250 partners around the world, including leading pharmaceutical, agrochemical, and emerging biotechnology companies. Atomwise has raised over $174 million from leading venture capital firms to advance our mission to make better medicines, faster. We’re at a critical time in history where our need for new kinds of medicines is greater than any time in human memory. Fortunately, we can leverage advancing technology and scientific breakthroughs to accelerate discovery. New data, new algorithms, new compute platforms lift all of us, enable our work on the hardest of problems, empower us to invent and create, and ultimately save one billion lives. Join us: www.atomwise.com/careers
2019
Angel Investor | Strategic Advisor
2019
BenevolentAI was founded in 2013 to improve quality of life and protect our way of life through technology. That belief has guided everything weve built. Today, theres more scientific knowledge being created than any human can process. We build AI systems that help humanity make sense of it - technology that can read, reason across, and explain the worlds biomedical knowledge. Our approach proved its value when our AI identified baricitinib as a potential Covid-19 treatment within 48 hours, a drug that went on to save lives globally. That wasnt about replacing scientists but extending what they could achieve. Now were making that capability accessible to the broader life sciences ecosystem through Qor, our strategic decision intelligence platform for biotech leaders. Technology in service of life. BenevolentAI is headquartered in London, UK.